ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib in Osteoarthritis Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02198924
Recruitment Status : Completed
First Posted : July 24, 2014
Last Update Posted : April 5, 2017
Sponsor:
Information provided by (Responsible Party):
Xisheng Weng, Peking Union Medical College Hospital

Brief Summary:
In mainland China, knee Osteoarthritis (OA) is the leading cause of disability in older persons. Total knee arthroplasty (TKA) is now generally regarded by orthopaedic surgeons and patients as an effective treatment for end-stage knee OA in order to relieve pain, correct joint deformity and improve the life quality of patients.However, TKA has been called as one of the most painful Orthopedics surgery due to the weight bearing characteristics of knee joint and the high demand of functional exercise within the 6-8 weeks post operation. The targeted application of selective cyclooxygenase (COX) -2 inhibitor, such as Parecoxib or Celecoxib, can significantly reduce the level of inflammatory reaction one and two days postoperation . In addition, the perioperative administration of Celecoxib can directly or indirectly relieve postoperative pain, improve articular function and eventually augment life quality of the patients . Recently, effective treatment of post-operative pain with intravenous followed by oral COX-2 specific inhibitor has been demonstrated in many post-operative pain models . Significant morphine sparing effect and reduction of opioid distressed symptoms were also observed. In China, many surgeons have accept it as a routine strategy for controlling pain post TKA to sequentially give parecoxib 40 mg intravenously twice daily for the first 3 days post surgery and then Celecoxib 200mg orally twice daily. Although satisfactory results of this combination treatment on short-term pain reduction and functional improvement has been observed in clinical practice, high quality evidence is still lacking to prove its effect on the medium or long-term functionality recovery. This study is being conducted to investigate the combination regimen with intravenous parecoxib followed by oral celecoxib for post-surgical analgesic treatment in osteoarthritis patients undergoing total knee arthroplastic (TKA) surgery. Subjects will receive double-blinded study medication consisting of parecoxib injection in analgesic doses or matching placebo followed by oral celecoxib in acute pain doses or matching placebo in a double-blinded fashion. The hypothesis is subjects treated with parecoxib/celecoxib will consume less morphine over the first 24 hours of postoperation period, achieve improved pain control over study period, a quicker return to functionality, and has less opioid adverse events than those treated with opioids alone over 6-week recovery phase.

Condition or disease Intervention/treatment Phase
Pain Inflammation Drug: Parecoxib and Celecoxib Drug: placebo Phase 4

Detailed Description:

Total knee arthroplasty (TKA), though generally regarded as an effective treatment for end-stage knee OA, has been called as "one of the most painful orthopedics surgeries" due to the weight bearing characteristics of knee joint and the high demand of functional exercise within the 6-8 weeks post operation.

Parecoxib and Celecoxib have been found to be able to relieve postoperative pain, spare opioid use, improve articular function and eventually augment life quality of the patients after TKA. In China, therefore, many surgeons have accept it as a routine strategy for controlling pain post TKA to sequentially use Parecoxib and then Celecoxib. However, high quality evidence is still lacking to prove its effect on the medium or long-term functionality recovery.

This multicenter, double blind, parallel-group randomized study, therefore, is aiming to evaluate efficacy and safety of postoperative intravenous Parecoxib sodium followed by oral Celecoxib in OA patients undergoing TKA. The hypothesis is that compared to placebo with opioids as rescue treatment, sequential use of Parecoxib/Celecoxib can achieve not only less morphine consumption over postoperatively 2 weeks, but also better pain control, quicker functional recovery, and less opioid related adverse events over 6-week recovery phase.

The primary objective of this study is to evaluate the morphine-sparing effects of the combination treatment with Parecoxib and Celecoxib versus placebo in subjects undergoing TKA. The secondary objective is to compare the effects of the combination treatment versus placebo on pain relief, inflammation control and functional rehabilitation after TKA. Total 86 subjects per group would have 90% power in detecting 100 mg or more in mean difference of morphine use on Day 14 between the two groups, assuming a common standard deviation of 200, and a two-sided alpha level of 0.05. This would result in a total 172 subjects. In consideration of 30% drop outs, 246 subjects would be adequate for the study. All subjects who meet the study inclusion and exclusion criteria will be randomly assigned in a 1:1 ratio to either Parecoxib/Celecoxib group or placebo group. The allocation or randomization will be study site based.Data will be collected using an Electronic Data Capture (EDC) under a strict intent-to-treat methodology, i.e., all the data of any Inform Consent Form signed subjects will be included in the study database.All subjects will be recruited from 4 study centers in China. The study will consist of 3 phases: an initial screening phase which must be completed within 30 days prior to randomization; a 6-week double blind treatment phase; and a 6 week follow up phase. A two-week wash-out procedure will be required before randomization for the patients with previous use of nonsteroidal antiinflammatory drug (NSAID) or COX-2 specific inhibitors.Variables considered continuous will be presented by descriptive statistics: number, mean, standard deviation, median, minimum, and maximum; and analyzed using parametric or non-parametric ANOVA, as appropriate. Variables considered categorical will be tabulated by frequency counts and percentages; and analyzed using Chi-square test or Fisher's exact tests. All the statistical tests will be two-sided with alpha=0.05, i.e., a p value <= 0.05 would be considered statistically significant.


Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 246 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Study to Evaluate Efficacy and Safety of Postoperative Intravenous Parecoxib Sodium Followed by Oral Celecoxib Post Total Knee Arthroplasty in Osteoarthritis Patients
Study Start Date : December 2013
Actual Primary Completion Date : November 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoarthritis

Arm Intervention/treatment
Experimental: Parecoxib and Celecoxib

Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.

Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic Tramadol Hydrochloride Sustained release tablets (TRAMCONTIN) as rescue analgesia if VAS score≧3.

Drug: Parecoxib and Celecoxib
Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.

Placebo Comparator: placebo

Patients in the control group are supplied with the corresponding placebo with the same instructions.

Patient-controlled intravenous analgesia (PCIA) with Morphine is administrated to all the subjects starting immediately post-anesthesia and ending at 24h after operation. As long as oral intake is feasible, both the two groups may receive centrally-acting analgesic TRAMCONTIN (Tramadol Hydrochloride Sustained release tablets) as rescue analgesia if VAS score≧3.

Drug: placebo
control patients are supplied with the corresponding placebo with the same instructions.




Primary Outcome Measures :
  1. Total narcotic use [ Time Frame: Post-operative 2 WEEKS ]
    The sum of the cumulative Morphine consumption over the first 24 hours postsurgical period and the narcotic drug consumption till 72h, 2w post operation will be converted to morphine equivalents. The converting of tramadol to Morphine equivalents is estimated as 150mg Tramadol equals to 10mg of Morphine injection.


Secondary Outcome Measures :
  1. Knee Society Score [ Time Frame: post-operation 6 weeks ]
    For more than 20 years, The Knee Society's Knee Scoring System (KSS) has served as a simple, objective way to measure a patient's functional ability before and after total knee arthroplasty (TKA). KSS questionnaire generates three domain scores: KSS function score (walking, stairs and use of knee supports), range of motion and KSS score (pain, range of motion and stability) scores.

  2. Western Ontario and McMaster Universities Arthritis(WOMAC) Index [ Time Frame: prior to operation and at 2w,4w and 6w post operation ]
    The WOMAC is a widely used, proprietary set of standardized questionnaires to evaluate the condition of patients with knee osteoarthritis , including pain, stiffness, and physical functioning of the joints. A WOMAC test takes about 12 minutes, and is among the most widely used assessments in arthritis research.

  3. Knee Society Score [ Time Frame: prior to operation and at 2w and 4w post operation ]
    For more than 20 years, The Knee Society's Knee Scoring System (KSS) has served as a simple, objective way to measure a patient's functional ability before and after total knee arthroplasty (TKA). KSS questionnaire generates three domain scores: KSS function score (walking, stairs and use of knee supports), range of motion and KSS score (pain, range of motion and stability) scores.

  4. Total Morphine use [ Time Frame: over the first 24 hours postsurgical period ]
    The cumulative Morphine consumption over the first 24 hours postsurgical period.

  5. Total narcotic use [ Time Frame: 72h, 4w, 6w post operation ]
    The cumulative Morphine consumption and opioid drug over the first 24 hours postsurgical period.

  6. Visual Analogue Scale [ Time Frame: prior to operation and at 24h, 48h, 72h, 2w, 4w and 6w post operation ]

    A Visual Analogue Scale (VAS) is a measurement instrument that tries to measure a characteristic or attitude that is believed to range across a continuum of values and cannot easily be directly measured.

    Operationally a VAS is usually a horizontal line, 100 mm in length, anchored by word descriptors at each end. The patient marks on the line the point that they feel represents their perception of their current state. The VAS score is determined by measuring in millimetres from the left hand end of the line to the point that the patient marks.


  7. EuroQol (EQ-5D) Score [ Time Frame: prior to operation and 72h, 2w, 4w and 6w post operation ]
    EQ-5D is a standard instrument for use as a measure of health outcome. EQ-5D is primarily designed for self-completion by respondents and is ideally suited for use in postal surveys, in clinics and face-to-face interviews. It is cognitively simple, taking only a few minutes to complete. Instructions to respondents are included in the questionnaire.


Other Outcome Measures:
  1. Knee circumference [ Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation ]
  2. skin temperature [ Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation ]
  3. Erythrocyte sedimentation rate(ESR) [ Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation ]
  4. C-Reactive Protein,CRP [ Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation ]
  5. interleukin-6 concentration in Synovial fluid [ Time Frame: 0h, 24h and 48h post operation ]
  6. interleukin-8 concentration in Synovial fluid [ Time Frame: 0h, 24h and 48h post operation ]
  7. interleukin-10 Synovial fluid concentration [ Time Frame: 0h, 24h and 48h post operation ]
  8. prostaglandin E2 concentration in Synovial fluid [ Time Frame: 0h, 24h and 48h post operation ]
  9. interleukin-6 concentration in Peripheral blood [ Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation ]
  10. interleukin-8 concentration in Peripheral blood [ Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation ]
  11. interleukin-10 concentration in Peripheral blood [ Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation ]
  12. prostaglandin E2 concentration in Peripheral blood [ Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation ]
  13. blood coagulation [ Time Frame: prior to operation and at 72h, 2w, 4w and 6w post operation ]
  14. The nature, incidence, duration, and severity of adverse events [ Time Frame: until 6w post operation ]
  15. Discontinuation due to adverse events [ Time Frame: until 6w post operation ]
  16. Adverse events [ Time Frame: during and after trial medication discontinuation ]
  17. complete blood count [ Time Frame: 2 weeks post operation ]
  18. blood chemistry parameters [ Time Frame: 6w post operation ]
  19. urinalysis test [ Time Frame: 2 weeks post operation ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. The subject is scheduled to undergo elective unilateral total knee arthroplasty because of OA, performed under a standardized regimen of general anesthesia, as specified in this protocol.
  2. Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
  3. The subject is a male or female over 18 years of age.
  4. Subjects of childbearing potential must agree to use an effective method of contraception throughout the study and for 42 days after the last dose of assigned treatment.
  5. Total duration of the surgical procedure is four hours or less.
  6. ASA grade 1-3 subjects.
  7. Subjects who are willing and able to comply with scheduled visits, treatment plan, laboratory tests, standardized rehabilitation scheme, and other study procedures.
  8. The subject is in satisfactory health as determined by the investigator on the basis of medical history and physical exam.
  9. The subject must demonstrate sufficient psychomotor dexterity and cognitive capacity to use intravenous (IV) patient-controlled analgesia(PCA).
  10. The subject who live near to the hospital may be considered prior for the concern of convenient and sufficient follow-up.

Exclusion Criteria:

  1. The subject requires a revision to previous knee arthroplasty and/or is having a bilateral knee arthroplasties.
  2. The subject requires an emergency knee arthroplasty.
  3. Subject uses opioids more than three days/ week prior to operation unless they discontinue the opioids two months prior to screen.
  4. Subject has a known hypersensitivity to COX-2 specific inhibitors, sulfonamides, lactose, NSAIDs, opioids or acetaminophen/paracetamol.
  5. The subject has a history of arthritis:, chronic pain, metastasis, and Paget's disease.
  6. The subject received any investigational medication within 30 days prior to the first dose of study medication.
  7. The subject has any known laboratory abnormality, which in the opinion of the investigator, would contraindicate study participation ≧1.5 times the upper limit of the normal reference range.
  8. The subject has an active malignancy of any type, or history of a malignancy (Subjects who have a history of basal cell carcinoma that has been successfully treated can be entered into the study.
  9. Subject had any condition, which could preclude use of NSAIDs or COX-2 specific inhibitors.
  10. The subject has active or suspected esophageal, gastric, pyloric channel, or duodenal ulceration history.
  11. The subject has received warfarin or other anticoagulants during the 30 days preceding the first dose of study medication.
  12. Subject is anticipated to require or requires treatment with lithium.
  13. Subject is American Society of Anesthesiologists(ASA) grade 4-5.
  14. The subject has a history of a psychiatric disorder requiring new or changing treatment
  15. The subject has a history of uncontrolled chronic disease or a concurrent clinically significant illness, medical condition.
  16. The subject has any cognitive impairment or other characteristics that would in the investigator's opinion preclude study participation or compliance with protocol mandated procedures.
  17. Subject has a history of asthma or bronchospasm, which requires treatment with glucocorticoids.
  18. Subject had a history of alcohol, analgesic or narcotic abuse.
  19. Subject has been previously randomized into the study
  20. Subjects who are investigational site staff members or relatives of those site staff
  21. Participation in other studies within 3 months before the current study begins and/or during study participation
  22. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation.
  23. Pregnant females, breastfeeding females, or males and females of childbearing potential not using effective contraception.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02198924


Locations
China
Peking Union Medical College Hospital
Beijing, China, 100730
Sponsors and Collaborators
Peking Union Medical College Hospital
Investigators
Principal Investigator: Xisheng Weng, M.D. Peking Union Medical College Hospital

Publications:
Du Q, Ge HJ, Zhu PF. Effects of perioperative analgesia on postoperative inflammatory response. Int J Anesth Resus., 2007, 28(1):48-53.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Xisheng Weng, Department of Orthopedics, Peking Union Medical College Hospital
ClinicalTrials.gov Identifier: NCT02198924     History of Changes
Other Study ID Numbers: WI1180091
First Posted: July 24, 2014    Key Record Dates
Last Update Posted: April 5, 2017
Last Verified: April 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by Xisheng Weng, Peking Union Medical College Hospital:
sequential administration
pain control
inflammation control
function recovery

Additional relevant MeSH terms:
Osteoarthritis
Inflammation
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Pathologic Processes
Celecoxib
Parecoxib
Tramadol
Cyclooxygenase 2 Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Analgesics, Opioid
Narcotics
Central Nervous System Depressants